Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
E-merge Capital Partners is a venture capital and growth equity firm founded in 2021, located in Solana Beach, California. The firm specializes in investing in innovative medical device companies and technologies, with a mission to enhance patient outcomes and improve quality of life. E-merge operates as part of a vertically integrated medtech venture platform, which includes Evolve Medtech Venture Studio for engineering and Pathway Medtech for manufacturing. This structure provides a comprehensive support system for portfolio companies, allowing them to navigate the complexities of product development and market entry.
Since its inception, E-merge has focused on early-stage investments, particularly in Class II medical devices within the cardiovascular and orthopedic sectors. The firm has established a reputation for its hands-on approach, actively engaging with portfolio companies to de-risk their innovations and accelerate their development timelines. E-merge Capital Partners has successfully raised its first fund, E-merge Fund I, which is currently operational and actively investing in promising medical technologies.
E-merge Capital Partners primarily invests in early-stage medical device companies, targeting pre-seed, seed, seed-plus, and Series A rounds. The firm emphasizes investments in Class II medical devices, particularly those that address needs in the cardiovascular and orthopedic sectors. E-merge seeks to partner with founders who are physician-entrepreneurs or medtech engineers, ideally at the pre-clinical or Investigational Device Exemption (IDE) stage. The firm’s investment strategy is centered around capital-efficient, de-risked opportunities, leveraging its integrated platform for engineering and manufacturing to compress time-to-prototype and minimize development costs.
In evaluating potential investments, E-merge Capital Partners looks for innovative technologies that can significantly enhance patient outcomes. The firm provides expertise in assessing and de-risking new opportunities, ensuring that portfolio companies receive the necessary support throughout their development journey. This includes hands-on involvement in operations and management, which is a hallmark of E-merge's operator-investor approach.
E-merge Capital Partners has invested in a range of notable medical device technologies, showcasing its commitment to advancing healthcare solutions. Key portfolio companies include:
These investments reflect E-merge's focus on developing technologies that address critical needs in the medical device sector, particularly in enhancing patient care and procedural efficiency.
Brad Klos - Managing Partner. Brad has a strong background in the medical device industry, having served as President & CEO of Traverse Vascular, which was acquired in June 2022. He co-founded SinglePass Transseptal, which was acquired in December 2023, and was also the CEO of Boa Medical, acquired in April 2025. His extensive experience in operational roles positions him as a key asset for E-merge's portfolio companies.
John M. Xitco - Managing Partner. John is a principal at E-merge Capital Partners and has a background in medical technology. He collaborates closely with Brad Klos and is involved in the firm's investment strategy and portfolio management.
Randy Werneth - Venture Partner. Randy brings a wealth of experience in venture capital and medical devices, contributing to E-merge's investment decisions and strategic direction.
Jim Pray - Limited Partner and Advisor. Jim provides advisory support to E-merge, leveraging his expertise in the medical device sector to guide portfolio companies.
Additionally, E-merge has a Business Advisory Board that includes experts in various fields such as intellectual property, regulatory affairs, and commercialization. Notable members include Gerard von Hoffman JD (Intellectual Property), Steve McQuillan (Regulatory Affairs & Quality Assurance), and Matt Schwartz JD (Venture & Growth Lending). The Medical Advisory Board features professionals like Steve Black MD (Vascular Surgeon) and Bill Nicholson MD (Interventional Cardiologist), providing critical insights into clinical applications and market needs.
To pitch E-merge Capital Partners, founders should submit their proposals through the firm's website at e-mergecapital.com. The pitch deck should include a comprehensive overview of the technology, market opportunity, competitive landscape, and team qualifications. E-merge prefers detailed information on the regulatory strategy and any clinical data available.
Response times may vary, but founders can expect feedback within a few weeks. Warm introductions are encouraged, as they can facilitate a more favorable review process. E-merge Capital Partners values clarity and thoroughness in pitch materials, as this reflects the founder's understanding of their business and the medical device market.
In April 2025, E-merge Capital Partners confirmed the acquisition of Boa Medical, marking a significant exit for the firm. This acquisition follows the successful exits of Traverse Vascular in June 2022 and SinglePass Transseptal in December 2023, showcasing E-merge's strong track record in the medical device sector.
The firm continues to actively invest in early-stage medical device companies, leveraging its integrated platform to support portfolio companies in their development journeys. E-merge's focus on capital-efficient, de-risked investments positions it well for future growth in the healthcare market.
What are E-merge Capital Partners' investment criteria?
E-merge Capital Partners focuses on early-stage medical device companies, particularly those developing Class II devices in the cardiovascular and orthopedic sectors. The firm seeks capital-efficient, de-risked opportunities that can significantly enhance patient outcomes.
How can I pitch to E-merge Capital Partners?
Founders can pitch E-merge Capital Partners through their website at e-mergecapital.com. It is recommended to include a detailed overview of the technology, market potential, and team background in the pitch deck.
What makes E-merge Capital Partners different from other VCs?
E-merge Capital Partners operates as part of a vertically integrated medtech venture platform, which includes in-house engineering and manufacturing capabilities. This unique structure allows them to provide hands-on support to portfolio companies, compressing development timelines and minimizing costs.
What is the geographic focus of E-merge Capital Partners?
The firm primarily invests in North America, with a strong emphasis on companies based in the United States. Their regulatory posture is FDA-centric, aligning with their focus on medical devices.
What is the typical check size for investments?
While specific check sizes are not publicly disclosed, E-merge Capital Partners focuses on early-stage investments, which typically range from pre-seed to Series A funding rounds.
What kind of support do portfolio companies receive?
E-merge Capital Partners provides extensive support to its portfolio companies, including operational assistance, access to engineering resources, and guidance on regulatory affairs. Their active operator-investor approach ensures that founders receive the necessary resources to navigate the challenges of bringing a medical device to market.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.